Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Rank and Yank? | Main | Peter Rost, Oddity »

September 28, 2004

Kicking the Dinosaur's Tail - Again

Email This Entry

Posted by Derek

Economist Mark Kleiman, in a clearheaded post on drug reimportation, says:

"No doubt, the politicians who are campaigning to permit pharmaceutical arbitrage are demagoging the issue by failing to mention the impact on innovation. But at least the argument they make – that allowing arbitrage would reduce prices to consumers – is more or less correct, and actually expresses their goal. The politicians who oppose arbitrage, by contrast -- including the Bush Administration -- largely try to hide behind the “safety” fig-leaf. That’s an insult to the intelligence of the voters."

Oh, yes indeed. My readers know that I've been banging on that particular washtub for a long time now, much good has it done. Here we go again, once more with feeling, from someone who works right here in the drug industry:

Canadian pharmaceuticals are safe. They're just as safe as ours. The reasons that reimporting them is a bad idea are economic ones. We need the money, and we've turned the US into the only place we can make it.

A more, um, detailed presentation of that point of view (from a passel of economists) can be found here. But the politics of the problem aren't in need of expert explication. Opponents of drug reimporation are trying to beat something (cheap drugs!) with nothing (no cheap drugs!) That's always a tough sell, so they - I can't bring myself to use the pronoun "we" - are trying to use irrelevant scare tactics instead. People are catching on

I think you can win a few short-term battles that way, at the cost of most surely losing the war. As I keep saying, the safety argument is one that can be addressed. As it will be, and where will my industry be then? Left wiping sweat from its forehead, stammering "But. . .but. . .there's actually another reason why this won't work. . ."

It'll be too late. The industry whose efforts I have devoted my adult working life to, the one that feeds my kids and keeps a roof over my head, is happily strapping itself to a barrel. It's making double-sure that the knots are firm and the cords are tight. The waterfall makes an awful, awful noise. . .

Comments (3) + TrackBacks (0) | Category: Drug Prices


COMMENTS

1. The Novice Chemist on September 28, 2004 11:19 PM writes...

Sitting around the group room table the other day, I actually came up with a pretty effective way to make money off of re-importation. It will only take a few counterfeiting cases (drugs labeled as such actually being placebos, etc.) before the re-importing public will be freaking out. That's where my idea comes in...

Mall kiosks (large ones, about the size of one of those jewelry repair shops), clear glass with white-lab-coated techs. Bring your re-imported tablets in, we'll run GC-MS, HPLC (whatever you want, for a price) on them and confirm their identities for you. Yes, ma'am, we'll check each and every tablet. That'll be 2 dollars per tablet, please.

Permalink to Comment

2. Jim Ancona on September 29, 2004 9:32 AM writes...

It seems to me that the reimportation problem is overblown. Here's why: If reimporting takes off, pharma companies are going to see a spike in Canadian demand. At that point they will threaten to limit supplies to Canada. The Canadian government will have three options:

1. Do nothing. Prices rise to Canadian consumers.
2. Break patents. This risks a trade war with their largest trading partner, the US.
3. Forbid re-export of drugs back to the US.

Number 3 seems like a no-brainer. The only people who get hurt are US consumers (who don't vote in Canada) and a few opportunistic mail-order pharmacies.

What am I missing?

The same analysis would seem to apply to any country that is a possible source for reimported drugs except for those without good control of their borders, like Mexico. And places like Mexico are precisely where quality issues are likely to be real.

Permalink to Comment

3. Derek Lowe on September 29, 2004 10:58 AM writes...

Jim, what I worry about is something like a further attempt to forbid the drug companies from limiting supplies. I think that the political benefits of being the Bringers Of Cheap Drugs will sweep other considerations aside once things really get going. Then we start in on price controls here in the US. . .

I think that the industry has painted itself into a corner by allowing other countries to lower their regulated prices so much, under the assumption that we could always make it up in the US. We're going to have to switch to a new, more painful business model eventually - I just hope it isn't all at once.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought